Abstract
Background
18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) has proven to be of
substantial benefit in imaging of sarcoma patients. We therefore investigated the
feasibility and benefit of combined PET/magnetic resonance imaging (MRI).
Methods
Twelve patients with sarcoma who underwent FDG PET/MRI for staging and response assessment
after chemotherapy were included.
Results
Based on contrast-enhanced MRI and application of Choi criteria, therapy response
was classified as stable disease in 6/12 patients (50%) and as partial remission in
6/12 patients (50%).
Conclusion
In sarcoma patients, response assessment using Choi criteria based on contrast-enhanced
MRI in comparison to FDG PET imaging only demonstrates slight correlation.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical ImagingAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Necrosis on FDG PET/CT correlates with prognosis and mortality in sarcomas.Am J Roentgenol. 2013; 201: 170-177https://doi.org/10.2214/AJR.12.9795
- Problems in grading soft tissue sarcomas.Am J Clin Pathol (Pathol Patterns Reviews). 2000; 114: S82-S89
- High-grade soft-tissue sarcomas: tumor response assessment—pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria.Radiology. 2009; 251: 447-456https://doi.org/10.1148/radiol.2512081403
- FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.Clin Cancer Res. 2009; 15: 2856-2863https://doi.org/10.1158/1078-0432.CCR-08-2537
- Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.J Clin Oncol. 2001; 19: 3203-3209
- Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.Clin Cancer Res. 2008; 14: 715-720https://doi.org/10.1158/1078-0432.CCR-07-1762
- 18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.Clin Cancer Res. 2012; 18: 2024-2031https://doi.org/10.1158/1078-0432.CCR-11-2139
- Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging—pilot study.Radiology. 2012; 264: 551-558https://doi.org/10.1148/radiol.12111942
- PET/MR for therapy response evaluation in malignant lymphoma: initial experience.MAGMA. 2013; 26: 49-55https://doi.org/10.1007/s10334-012-0342-7
- Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.Invest Radiol. 2013; 48: 263-272https://doi.org/10.1097/RLI.0b013e31828234d0
- Hybrid PET/MR imaging in two sarcoma patients—clinical benefits and implications for future trials.Int J Clin Exp Med. 2014; 7: 640-648
- PET/MRI imaging in high-risk sarcoma: first findings and solving clinical problems.Case Rep Oncol Med. 2013; 2013: 793927https://doi.org/10.1155/2013/793927
- Oncologic PET/MRI, Part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma.J Nucl Med. 2012; https://doi.org/10.2967/jnumed.112.109306
- Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.Mol Cancer Ther. 2009; 8: 449-457https://doi.org/10.1158/1535-7163.MCT-08-0848
- Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.Lancet Oncol. 2007; 8: 595-602https://doi.org/10.1016/S1470-2045(07)70175-4
- Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.Ann Oncol. 2012; 23: 771-776https://doi.org/10.1093/annonc/mdr265
- Whole-body diffusion-weighted MRI with apparent diffusion coefficient mapping for early response monitoring in multiple myeloma: preliminary results.AJR Am J Roentgenol. 2011; 196: W790-W795https://doi.org/10.2214/AJR.10.5979
- Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity—a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging.Eur J Radiol. 2014; 83: 1655-1664https://doi.org/10.1016/j.ejrad.2014.05.027
- Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.Cancer. 2012; https://doi.org/10.1002/cncr.27624
- Selection of response criteria for clinical trials of sarcoma treatment.Oncologist. 2008; 13: 32-40https://doi.org/10.1634/theoncologist.13-S2-32
- Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.Clin Cancer Res. 2005; 11: 2785-2808https://doi.org/10.1158/1078-0432.CCR-04-2626
- Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy.Cancer. 2005; 103: 339-348https://doi.org/10.1002/cncr.20769
- Utility of positron emission tomography in sarcomas.Curr Opin Oncol. 2006; 18: 369-373https://doi.org/10.1097/01.cco.0000228744.49294.12
- Correction of scan time dependence of standard uptake values in oncological PET.EJNMMI Res. 2014; 4: 18https://doi.org/10.1186/2191-219X-4-18
- Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.J Clin Oncol. 2007; 25: 1753-1759https://doi.org/10.1200/JCO.2006.07.3049
- Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.Hell J Nucl Med. 2011; 14: 8-14
- Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets.Nuklearmedizin. 2012; 51: 9-16https://doi.org/10.3413/Nukmed-0419-11-07
- Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.Eur J Cancer. 1999; 35: 1773-1782
- An application of hierarchical kappa-type statistics in the assessment of majority agreement among multiple observers.Biometrics. 1977; 33: 363-374
- PET/MRI for preoperative planning in patients with soft tissue sarcoma: a technical report of two patients.Case Rep Med. 2013; 2013: 791078https://doi.org/10.1155/2013/791078
- Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.J Clin Oncol. 2007; 25: 5435-5441https://doi.org/10.1200/JCO.2007.12.2473
- Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters.Eur J Nucl Med Mol Imaging. 2010; 37: 1842-1853https://doi.org/10.1007/s00259-010-1484-3
- Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study.Lancet. 2012; 380: 499-505https://doi.org/10.1016/S0140-6736(12)60815-0
- The significance of size change of soft tissue sarcoma during preoperative radiotherapy.Eur J Surg Oncol. 2010; 36: 678-683https://doi.org/10.1016/j.ejso.2010.05.021
Article info
Publication history
Published online: June 03, 2015
Accepted:
May 26,
2015
Received in revised form:
May 6,
2015
Received:
February 1,
2015
Identification
Copyright
© 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
